Initiating warfarin therapy: 5 mg versus 10 mg.

Item

http://www.wikidata.org/entity/Q35937712

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Initiating warfarin therapy: 5 mg versus 10 mg.

@ast

Initiating warfarin therapy: 5 mg versus 10 mg.

@en

type

Item

label

Initiating warfarin therapy: 5 mg versus 10 mg.

@ast

Initiating warfarin therapy: 5 mg versus 10 mg.

@en

prefLabel

Initiating warfarin therapy: 5 mg versus 10 mg.

@ast

Initiating warfarin therapy: 5 mg versus 10 mg.

@en

P1476

Initiating warfarin therapy: 5 mg versus 10 mg.

@en

P2093

Courtney D Eckhoff

http://www.w3.org/2001/XMLSchema#string

Nancy L Shapiro

http://www.w3.org/2001/XMLSchema#string

Robert J Didomenico

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Hemorrhagic complications of anticoagulant treatment.

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects.

A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care.

A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment.

Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin.

Major bleeding after hospitalization for deep-venous thrombosis.

Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy.

P304

2115-2121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1E083

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15522981

http://www.w3.org/2001/XMLSchema#string